A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2002, Pages 381-388

  Malik, A H ^a   Kumar, K S ^a   Malet, P F ^a   Ostapowicz, G ^a   Adams, G ^a   Wood, M ^a   Yarbrough, K ^a   Jones, A ^a   Lee, W M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; MALE; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT FAILURE;

EID: 0036188804     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01201.x     Document Type: Article

References (30)

1. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial
2. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized double blind, placebo-controlled trial
3. High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C. A randomized controlled trial
4. Treatment of chronic hepatitis C with high dose interferon alpha 2b. A multi-center study
5. Results of long-term interferon treatment in non-A, non-B/C chronic active hepatitis
6. High dose interferon alfa-2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial
7. Dose dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha
8. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
9. Randomized trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
10. Randomized, double-blind, placebo controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C
11. Classification of chronic hepatitis: Diagnosis, grading and staging
12. Reporting results of cancer treatment
13. Ultrarapid hepatitis C virus clearance by daily high dose interferon in non-responders to standard therapy
14. A controlled study to determine the optimal dose regimen of interferon alpha-2b in chronic hepatitis C
15. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C
16. A randomized controlled trial of high dose maintenance interferon therapy in chronic hepatitis C
17. Recombinant interferon alpha-2a for treatment of chronic hepatitis C: Results of a multi-center randomized controlled dose study
18. A randomized controlled trial of daily vs three times weekly interferon alpha-2a in patients with chronic hepatitic HCV and either elevated or persistently normal ALT
19. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
20. Raising the dose of interferon does not improve the response in chronic hepatitis C
21. Dose increase augments response rate to interferon alpha in chronic hepatitis C
22. Re-treatment of chronic hepatitis C with consensus interferon
23. Retreatment with interferon alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
24. Interim analysis of a randomized controlled trial of ribavirin and high dose interferon alpha in interferon nonresponders with chronic hepatitis C
25. Value of high-dose interferon alpha in chronic viral hepatitis C patients non-responding to a 1st treatment. Pilot study, prospective and randomized trial
26. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C
27. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose
28. Early HCV RNA results predict interferon treatment outcomes in chronic hepatitis C
29. Factors predictive of a beneficial response to therapy of hepatitis C
30. Side effects of high dose interferon therapy for chronic hepatitis C